GenMont Biotech Inc

GenMont Biotech Inc has a market capitalization of TWD 1.51 billion and a price-to-earnings ratio of 26.32, indicating a moderate valuation relative to earnings. The company's price-to-book ratio of 1.13 suggests that the market values the company slightly above its book value. The liquidity position is characterized by a current ratio of 4.28, which is significantly above the industry median, indicating strong short-term liquidity. Profitability metrics show a return on equity (ROE) of 4.3% and a return on assets (ROA) of 3.44%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming in terms of capital efficiency and asset utilization compared to its peers. The gross profit margin is 62.7%, which is in line with the industry median, but the operating margin of 14.4% is below the median, indicating higher operating costs relative to revenue. The company's revenue is primarily derived from the sale of functional lactobacillus products, with a significant portion distributed in the domestic market. There is no detailed breakdown of geographic revenue concentration in the provided data, but the company does export to overseas markets. The lack of segment-specific revenue data limits the ability to assess geographic diversification. Looking at the growth trajectory, the company's revenue for the latest period is TWD 401.23 million. While the provided data does not include historical revenue figures, the current financial snapshot suggests a stable revenue base. The outlook for the current fiscal year is neutral, with no significant growth or decline expected. The company's capital expenditure is negative, indicating a reduction in capital spending, which may signal a focus on cost optimization or a slowdown in expansion. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has a debt-to-equity ratio of 0.08, which is well below the industry median, suggesting a conservative capital structure. However, the key flag of net cash being negative after subtracting total debt indicates potential liquidity constraints. The company has not issued additional shares recently, and there is no indication of dilution pressure in the near term. Recent events include the latest financial filing, which provides the most recent snapshot of the company's financial position. There are no recent earnings call transcripts or significant corporate actions disclosed in the provided data. The company's focus on functional lactobacillus products aligns with current trends in health and wellness, which could provide a growth opportunity in the long term.